By Drug Class:
By Distribution Channel
By Disease Indications
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Immunology Drugs Market Snapshot
Chapter 4. Global Immunology Drugs Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Drug Class Estimates & Trend Analysis
5.1. By Drug Class & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Drug Class:
5.2.1. Monoclonal antibody
5.2.2. Fusion Proteins
5.2.3. Immunosuppressant
5.2.4. Polyclonal antibody
5.2.5. Other Drug Class
Chapter 6. Market Segmentation 2: By Distribution Channel Estimates & Trend Analysis
6.1. By Distribution Channel & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Distribution Channel:
6.2.1. Hospital Pharmacies
6.2.2. Retail Pharmacies
6.2.3. Online Pharmacies
6.2.4. Other Distribution Channel
Chapter 7. Market Segmentation 3: By Disease Indications Estimates & Trend Analysis
7.1. By Disease Indications & Market Share, 2024 & 2034
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Disease Indications:
7.2.1. Rheumatoid Arthritis
7.2.2. Psoriatic Arthritis
7.2.3. Plaque Psoriasis
7.2.4. Ankylosing Spondylitis
7.2.5. Inflammatory Bowel disease
7.2.6. Other disease Indication
Chapter 8. Immunology Drugs Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America Immunology Drugs Market revenue (US$ Million) estimates and forecasts By Drug Class, 2021-2034
8.1.2. North America Immunology Drugs Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2021-2034
8.1.3. North America Immunology Drugs Market revenue (US$ Million) estimates and forecasts by Disease Indications, 2021-2034
8.1.4. North America Immunology Drugs Market revenue (US$ Million) estimates and forecasts by country, 2021-2034
8.2. Europe
8.2.1. Europe Immunology Drugs Market revenue (US$ Million) By Drug Class, 2021-2034
8.2.2. Europe Immunology Drugs Market revenue (US$ Million) By Distribution Channel, 2021-2034
8.2.3. Europe Immunology Drugs Market revenue (US$ Million) estimates and forecasts by Disease Indications, 2021-2034
8.2.4. Europe Immunology Drugs Market revenue (US$ Million) by country, 2021-2034
8.3. Asia Pacific
8.3.1. Asia Pacific Immunology Drugs Market revenue (US$ Million) By Drug Class, 2021-2034
8.3.2. Asia Pacific Immunology Drugs Market revenue (US$ Million) By Distribution Channel, 2021-2034
8.3.3. Asia Pacific Immunology Drugs Market revenue (US$ Million) estimates and forecasts by Disease Indications, 2021-2034
8.3.4. Asia Pacific Immunology Drugs Market revenue (US$ Million) by country, 2021-2034
8.4. Latin America
8.4.1. Latin America Immunology Drugs Market revenue (US$ Million) By Drug Class, 2021-2034
8.4.2. Latin America Immunology Drugs Market revenue (US$ Million) By Distribution Channel, 2021-2034
8.4.3. Latin America Immunology Drugs Market revenue (US$ Million) estimates and forecasts by Disease Indications, 2021-2034
8.4.4. Latin America Immunology Drugs Market revenue (US$ Million) by country, 2021-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa Immunology Drugs Market revenue (US$ Million) By Drug Class, 2021-2034
8.5.2. Middle East & Africa Immunology Drugs Market revenue (US$ Million) By Distribution Channel, 2021-2034
8.5.3. Middle East & Africa Immunology Drugs Market revenue (US$ Million) estimates and forecasts by Disease Indications, 2021-2034
8.5.4. Middle East & Africa Immunology Drugs Market revenue (US$ Million) by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Eli Lilly and Company
9.2.2. AbbVie Inc
9.2.3. F.Hoffmann-La roche Ltd
9.2.4. Amgen Inc
9.2.5. Pfizer
9.2.6. Novartis
9.2.7. Astellas
9.2.8. Alector
9.2.9. ImmuNext
9.2.10. Merck sharp & Dohme Corp.
9.2.11. UCB SA
9.2.12. Other Prominent Players
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.